Drug therapy for hepatitis B

Advances in Internal Medicine

Volumn 46, Issue , 2001, Pages 107-135

  Regev, Arie ^a   Schiff, Eugene R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; INTERFERON; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DISEASE COURSE; FEMALE; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; MALE; PROGNOSIS; REVIEW;

ADENINE; ANTIVIRAL AGENTS; DISEASE PROGRESSION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; PHOSPHONIC ACIDS; PROGNOSIS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035219646     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (125)

1. Alter MJ, Mast EE: The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 23:437-455, 1994.
2. Lee WM: Hepatitis B virus infection. N Eng J Med 337:1733-1745, 1997.
3. Chan HL, Ghany MC, Lok ASF: Hepatitis B, in Schiffs Diseases of the Liver, ed 8. Philadelphia-New York, Lippincott-Raven, 1999, pp 757792.
4. Lok AS, Lai CL, Wu PC, et al: Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 126:492-499, 1987.
5. Alter MJ, Hadler SC, Margolis HS, et al: The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 263:1218-1222, 1990.
6. Edgington TS, Chisari FV: Immunological aspects of hepatitis B infection. Am J Med Sei 270:213-218, 1975.
7. Peters M, Vierling J, Gershwin ME, et al: Immunology and the liver. Hepatology 13:977-994, 1991.
8. Peters M: Mechanisms of action of Interferon. Semin Liver Dis 9:235245, 1989.
9. Pestka S, Langer JA, Zoon KC, et al: Interferons and their actions. Annu RevBiochem 56:727-777, 1987.
10. Weissmann C, Weber H: The Interferon genes. Prog Nucleic Acid Res Mol Biol 33:251-300, 1986.
11. Staeheli P: Interferon-induced proteins and the anti-viral state. Adv Virus Res 38:147-200, 1990.
12. Pignatelli M, Waters J, Brown D, et al: HLA class I antigen on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during Interferon therapy in chronic hepatitis B virus infection. Hepatology 6:349-353,1986.
13. Scully LJ, Brown D, Lloyd C, et al: Immunological studies before and during interferon therapy in chronic HBV infection: Identification of factors predicting response. Hepatology 12:1111-1117,1990.
14. Perrillo R, Tamburro C, Regenstein F, et al: Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Hepatology 109:908-916,1995.
15. Hoofnagle JH, Di Bisceglie AM: Treatment of chronic viral hepatitis. N Engl J Med 336:347-356,1997.
16. Greenberg HB, Pollard RB, Lutwick LI, et al: Effect of human interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295:517-522,1976.
17. Alexander GJ, Brahm J, Pagan EA, et al: Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 2:66-69, 1987.
18. Perrillo RP, Regenstein FG, Peters MG, et al: Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis: A randomized controlled trial. Ann Intern Med 109:95-100, 1988.
19. Perrillo RP, Schiff ER, Davis GL, et al: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Intervention Therapy Group. N Engl J Med 323:295-301,1990.
20. Hoofnagle JH, Peters M, Müllen BCD, et al: Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 95:1318-1325,1988.
21. Di Bisceglie AM, Fong TL, Fried MW, et al: A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 88:1887-1892,1993.
22. Sokal EM, Conjeevaram HS, Roberts EA, et al: Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial. Gastroenterology 114:988-995,1998.
23. Wong DK, Cheung AM, O'Rourke K, et al: Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312-323,1993.
24. Carreno V, Marcellin P, Hadziyannis S, et al: Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 30:277-282,1999.
25. Janssen HL, Gerken G, Carreno V, et al: Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 30:238-243,1999.
26. Niederau C, Heintges T, Lange S, et al: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334:1422-1427,1996.
27. Lau DTY, Everhart J, Kleiner DE, et al: Long-term follow-up in patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113:1660-1667,1997.
28. Chisari FV: Cytotoxic T cells and viral hepatitis J Clin Invest 99:14721477,1997.
29. Lok AS, Liang RH, Chiu EK, et al: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188,1991.
30. Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology 26(suppl 1):S112-S121,1997.
31. Perrillo RP, Mason AL: Therapy for hepatitis B virus infection. Gastroenterol Clin North Am 23:581-601,1994.
32. Renault PF, Hoofnagle JH, Park Y, et al: Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 147:1577-1580, 1987.
33. Comanor L, Minor J, Conjeevaram HS, et al: Impact of interferon-a therapy on growth of children with chronic hepatitis B virus disease. Hepatology 30:344A, 1999.
34. Dusheiko G, Di Bisceglie A, Bowyer S, et al: Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology 5:556-560, 1985.
35. Brook MG, Karayiannis P, Thomas HC: Which patient with chronic hepatitis B virus infection will respond to alpha-interferon therapy? Hepatology 10:761-763,1989.
36. Saracco G, Mazzella G, Rosina F, et al: A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology 10:336-341, 1989.
37. Lok ASF, Wu PC, Lai CL, et al: A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102:2091-2097, 1992.
38. Heijtink RA, Kruining J, Honkoop P, et al: Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B J Med Virol 53:282287,1997.
39. Lok AS, Lai CL, Wu PC, et al: Long-term follow-up in a randomized controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 2:298-302,1988.
40. Lok ASF, Lai CL: A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 115:11301133,1989.
41. Jarvis B, Faulds D: Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1:101-141,1999.
42. Johnson MA, Verpooten GA, Daniel MJ, et al: Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol 46:21-27,1998.
43. Johnson MA, Horak J, Breuel P: The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol 54:363-366, 1998.
44. Perrillo KP, Schiff ER, Dienstag JL, et al: Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B. Hepatology 30:301A, 1999.
45. Yao FYK, Bass NM: Lamivudine reverses severe hepatic decompensation due to replicating hepatitis B infection in patients with cirrhosis. Hepatology 30:346A, 1999.
46. Grellier L, Mutimer D, Ahmed M, et al: Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212-1215, 1996.
47. Markowitz JS, Martin P, Conrad AJ, et al: Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585589, 1998.
48. Terrault NA, Wright TL, Roberts JP, et al: Combined short-term hepatitis B immunoglobulin (HBIG) and long-term lamivudine (LAM) versus HBIG monotherapy as hepatitis B virus prophylaxis in liver transplant recipients. Hepatology 28:389A, 1998.
49. Tassopoulos NC, Volpes R, Pastore G, et al: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNApositive (precore mutant) chronic hepatitis B. Hepatology 29:889-896, 1999.
50. Benhamou Y, Katlama C, Lunel F, et al: Effects of lamivudine on replication of hepatitis B virus in HTV-infected men. Ann Intern Med 125:705-712, 1996.
51. CAESAR Coordinating Committee: Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-I infection: The CAESAR trial. Lancet 349:1413-1421, 1997.
52. Dienstag JL, Perrillo RP, Schiff ER, et al: A preliminary trial of lamivudine in chronic hepatitis B infection. N Engl J Med 333:1657-1661, 1995.
53. Honkoop P, De Man RA, Niesters HG, et al: Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: Evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepatol 5:307-312, 1998.
54. Nevens F, Main J, Honkoop P, et al: Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterology 113:1258-1263, 1997.
55. Lai CL, Ching CK, Tung AK, et al: Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology 25:241-244,1997.
56. Lai CL, Chien RN, Leung NWY, et al: A one year trial of lamivudine for chronic hepatitis B. N Eng J Med 339:61-68, 1998.
57. Dienstag JL, Schiff ER, Wright TL, et al: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Eng J Med 341:1256-1263, 1999.
58. Dienstag JL, Schiff ER, Mitchell M, et al: Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy. Hepatology 30:1082-1087, 1999.
59. Leung N, Dienstag J, Schiff E: Clinical safety profile of lamivudine treatment in a large cohort of hepatitis B patients. Hepatology 28:587A, 1998.
60. Perry CM, Faulds D: Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 53:657-680, 1998.
61. Benhamou Y, Bochet M, Thibault V, et al: Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30:1302-1306, 1999.
62. Leung NWY, Lai CL, Chang TT, et al: Three years lamivudine therapy in chronic HBV JHepatol 30 (suppl 1):59, 1999.
63. Alien MI, Deslaurier M, Andrews CW, et al: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677, 1998.
64. Melegari M, Scaglioni PP, Wands JR: Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633, 1998.
65. Schiff ER, Karayalcin S, Grimm I, et al: A placebo controlled study of lamivudine and Interferon alpha-2b in patients with chronic hepatitis B who previously failed Interferon therapy. Hepatology 28:338A,1998.
66. Heathcote J, Schalm SW, Cianciara J, et al: Lamivudine and intron A combination treatment in patients with chronic hepatitis B infection. J Hepatol 28 (suppl 1):43, 1998.
67. Mutimer D, Naoumov N, Honkoop P, et al: Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic B infection: Results of a pilot study. J Hepatol 28:923-929, 1998.
68. Deeks SG, Collier A, Lalezari J, et al: The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: A randomized, double-blind, placebo-controlled trial, f Infect Dis 176:1517-1523, 1997.
69. Gilson RJC, Chopra K, Murray-Lyon I, et al: Placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection. Hepatology 24 (suppl 1):281A, 1996.
70. Noble S, Goa KL: Adefovir dipivoxil. Drugs 58:479-487, 1999.
71. Xiong X, Flores C, Yang H, et al: Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673, 1998.
72. Ono-Nita SK, Kato N, Shiratori Y, et al: Susceptibility of lamivudineresistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 103:1635-1640, 1999.
73. Perrillo R, Schiff E, Magill A, et al: In vivo demonstration of sensitivity of YMDD variants to adefovir. Gastroenterology 116:A1261,1999.
74. Boyd MR, Safrin S, Kern ER: Penciclovir: A review of its spectrum of activity, selectivity and cross resistance pattern. Antiviral Chem Chemother4 (suppl 1):3-11,1993.
75. Lin E, Luscombe C, Wang YY, et al: The guanine nucleotide analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 40:413-418,1996.
76. Shaw T, Mok SS, Locarnini SA: Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 24:996-1002,1996.
77. Korba BE, Boyd MR: Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 40:1282-1284,1996.
78. Main J, Brown JL, Howells G, et al: A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection J Viral Hepatol 3:211-215,1996.
79. Marques AR, Lau DT, McKenzie R, et al: Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. J Infect Dis 178:1483-1487,1998.
80. Aye TT, Bartholomeusz A, Shaw T, et al: Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 26:1148-1153,1997.
81. Pichoud C, Seigneres B, Wang Z, et al: Transient selection of hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 29:230-237, 1999.
82. Buti M, Jardi R, Cotrina M, et al: Transient emergence of hepatitis B in patients with chronic hepatitis B resistant to lamivudine. J Hepatol 28:510-513,1998.
83. Genovesi EV, Lamb L, Medina I, et al: Efficacy of the carbocyclic 2'deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 42:32093217,1998.
84. Cullen JM, Smith SL, Davis MG, et al: In vivo antiviral activity and pharmacokmetics of (-)-cis-5-fluoro-l-[2-(hydroxymethyl)-l,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 41:2076-2082,1997.
85. Carman WF, Jacyna MR, Hadziyannis S, et al: Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2:588-591,1989.
86. Brunette- MR, Oliver! F, Rocca G, et al: Natural course and response to Interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 10:198-202,1989.
87. Laras A, Koskinas J, Avgidis K, et al: Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients J Viral Hepat 5:241-248,1999.
88. Brunetto MR, Giarin M, Saracco G, et al: Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 105:845-850,1993.
89. Zhang X, Zoulim F, Habersetzer F, et al: Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B J Med Virol 48:8-16, 1996.
90. Brunetto MR, Oliven F, Colombatto P, et al: Treatment of chronic antiHBe-positive hepatitis B with interferon-alpha J Hepatol 22(suppl 1): 42-44,1995.
91. Fattovich G, Mclntyre G, Hursz M, et al: Hepatitis B virus precore/core variation and interferon therapy. Hepatology 22:13551362,1995.
92. Lampertico P, Del Ninno E, Manzin A, et al: A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 26:1621-1625,1997.
93. Pastore G, Santantonio T, Milella M, et al: Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon JHepatol 14:221-225,1992.
94. Perrillo RP, Regenstein FG, Roodman ST: Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med 105:382-383,1986.
95. Gilson RJC, Hawkins AE, Beecham MR, et al: Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 11:597-606,1997.
96. Wong DK, Yim C, Naylor CD, et al: Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population. Gastroenterology 108:165-171, 1995.
97. Scharschmidt BF, Held MJ, Hollander HH, et al: Hepatitis B in patients with HTV infection: Relationship to AIDS and patient survival. Ann Mem Med 117:837-838,1992.
98. Cacciola I, Pollicino T, Squadrito G, et al: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341:22-26,1999.
99. Weltman MD, Brotodihardjo A, Crewe EB, et al: Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment J Viral Hepat 2:39-45,1995.
100. Liaw YF, Chien RN, Lin SM, et al: Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 17:449-452,1997.
101. Zignego AL, Fontana R, Puliti S, et al: unpaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol 142:535-544,1997.
102. Terrault NA, Wright TL: Hepatitis B virus infection and liver transplantation. Gut 40:568-571, 1997.
103. Samuel D, Muller R, Alexander G, et al: Liver transplantation in European patients with the hepatitis B surface antigen. N Engl ] Med 329:1842-1847, 1993.
104. Samuel D, Bismuth A, Mathiew D, et al: Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 337:813-815, 1991.
105. McGory RW, Ishitani MB, Oliveira WM, et al: Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive immunization. Transplantation 61:1358-1364, 1996.
106. Terrault NA, Zhou S, Combs C, et al: Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24:1327-1333, 1996.
107. Dickson RC, Wright RM, Bacchetta MD, et al: Quality of life of hepatitis B and C patients after liver transplantation. Clin Transplantation 11:285, 1997.
108. Ghany MG, Ayola B, Villamil FG, et al: Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27:213-222, 1998.
109. Protzer-Knolle U, Naumann U, Bartenschlager R, et al: Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254-263, 1998.
110. Mutimer DJ, Grellier L, Barrett ÇA, et al: Lamivudine without HBIG for prevention of graft infection by hepatitis B: Long-term follow-up. Hepatology 30:301A, 1999.
111. Chisari FV: Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:29-60, 1995.
112. Boni C, Bertoletti A, Penna A, et al: Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B J Clin Invest 102:968975, 1998.
113. Reherrnann B, Lau D, Hoofnagle JH, et al: Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97:1655-1665, 1996.
114. Mancini M, Hadchouel M, Tiollais P, et al: Induction of anti-hepatitis b surface antigen (HBsAg) antibodies in HBsAg transgenic mice: A possible way of circumventing nonresponders to HBsAg J Med Virol 39:74,1993.
115. Pol S, Driss F, Carnot F, et al: Vaccination against hepatitis b virus: An efficient immunotherapy against hepatitis B multiplication. CRAcad Sei III 316:688-691, 1993.
116. Couillin I, Pol S, Mancini M, et al: Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens J Infect Dis 180:15-26, 1999.
117. Milich DR, McLachlan A, Chisari FV, et al: Immune response to the pre-S(l) region of the hepatitis B surface antigen (HbsAg): A pre-S(l)specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of the HBsAg J Immunol 137:322, 1986.
118. Shouval D, Ilan Y, Adler R, et al: Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-Sl and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 12:1453-1459, 1994.
119. Waters JA, Bailey C, Love C, et al: A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies J Med Virol 54:1-6, 1998.
120. Pol S, Couillin I, Michel ML, et al: Immunotherapy of chronic hepatitis B by anti HBV vaccine. Acta Gastroenterol Belg 61:228-233, 1998.
121. Heathcote J, McHutchison J, Lee S, et al: A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 30:531-536, 1999.
122. von Weizsacker F, Kock J, Wieland S, et al: Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis. Hepatology 30:308315, 1999.
123. zu Putlitz J, Wieland S, Blum HE, et al: Antisense RNA complementary to hepatitis B virus specifically inhibit viral replication. Gastroenterology 115:702-713, 1998.
124. Offensperger WB, Offensperger S, Walter E, et al: In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 12:1257-1262, 1993.
125. Hoofnagle JH, Lau D: New therapies for chronic hepatitis B J Viral Hepat4 (suppl 1):41-50, 1997.